Skip to main content
Top
Published in: PharmacoEconomics 12/2019

01-12-2019 | Original Research Article

A Comparison of Different Analysis Methods for Reconstructed Survival Data to Inform Cost‑Effectiveness Analysis

Authors: Sandjar Djalalov, Jaclyn Beca, Emmanuel M. Ewara, Jeffrey S. Hoch, PhD

Published in: PharmacoEconomics | Issue 12/2019

Login to get access

Abstract

Objectives

The aim of this study was to use Microsoft Excel spreadsheet software to fit parametric survival distributions. We also explain the differences between individual patient data (IPD) and survival data reconstructed in Excel and SAS.

Methods

Three sets of patient data on overall survival were compared using different methods: ‘original’ IPD, ‘reconstructed SAS’, and ‘reconstructed Excel’. The best-fit distribution was selected using visual observation, supported by linear plots of predicted probabilities, goodness-of-fit coefficients, and the sum of squared error of prediction. Outcomes included the incremental cost-effectiveness ratio (ICER), incremental net benefit (INB), incremental cost, and life-years gained over short-term and lifetime horizons. These were compared for different data sets.

Results

In this example, log-normal, log-logistic, and Weibull distributions showed best-fit with the visual tests and goodness-of-fit statistics. Weibull and exponential distributions showed significant differences compared with IPD data. Data on short-term (5 years) time horizons produced by different data re-creation methods showed closeness with data reconstructed from SAS. The ICER and INB results were dependent on the time horizon and selected parametric distribution from the model.

Conclusions

Different approaches used in fitting parametric survival distributions yielded predicted probabilities that substantially differed from those using original IPD. Our study highlights the importance of following guidelines for economic evaluations with a systematic approach to parametric survival analysis techniques in order to select best fitting parametric survival distributions.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ishak KJ, Kreif N, Benedict A, Muszbek N. Overview of parametric survival analysis for health-economic applications. PharmacoEconomics. 2013;31:663–75.CrossRef Ishak KJ, Kreif N, Benedict A, Muszbek N. Overview of parametric survival analysis for health-economic applications. PharmacoEconomics. 2013;31:663–75.CrossRef
2.
go back to reference Goel MK, Khanna P, Kishore J. Understanding survival analysis: Kaplan–Meier estimate. Int J Ayurveda Res. 2010;1:274–8.CrossRef Goel MK, Khanna P, Kishore J. Understanding survival analysis: Kaplan–Meier estimate. Int J Ayurveda Res. 2010;1:274–8.CrossRef
3.
go back to reference Ishak KJ Parametric Survival Analysis Overview Presentation at ISPOR Europe, Nov. 2011. Ishak KJ Parametric Survival Analysis Overview Presentation at ISPOR Europe, Nov. 2011.
4.
go back to reference Latimer NR. Survival analysis for economic evaluations alongside clinical trials—extrapolation with patient-level data: inconsistencies, limitations, and a practical guide. Med Decis Mak. 2013;33:743–54.CrossRef Latimer NR. Survival analysis for economic evaluations alongside clinical trials—extrapolation with patient-level data: inconsistencies, limitations, and a practical guide. Med Decis Mak. 2013;33:743–54.CrossRef
5.
go back to reference Hoyle MW, Henley W. Improved curve fits to summary survival data: application to economic evaluation of health technologies. BMC Med Res Methodol. 2011;11:139.CrossRef Hoyle MW, Henley W. Improved curve fits to summary survival data: application to economic evaluation of health technologies. BMC Med Res Methodol. 2011;11:139.CrossRef
6.
go back to reference Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan–Meier survival curves. BMC Med Res Methodol. 2012;12:9.CrossRef Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan–Meier survival curves. BMC Med Res Methodol. 2012;12:9.CrossRef
7.
go back to reference Diaby V, Adunlin G, Montero AJ. Survival modeling for the estimation of transition probabilities in model-based economic evaluations in the absence of individual patient data: a tutorial. PharmacoEconomics. 2014;32:101–8.CrossRef Diaby V, Adunlin G, Montero AJ. Survival modeling for the estimation of transition probabilities in model-based economic evaluations in the absence of individual patient data: a tutorial. PharmacoEconomics. 2014;32:101–8.CrossRef
8.
go back to reference Davies C, Briggs A, Lorgelly P, Garellick G, Malchau H. The, “hazards” of extrapolating survival curves. Med Decis Mak. 2013;33:369–80.CrossRef Davies C, Briggs A, Lorgelly P, Garellick G, Malchau H. The, “hazards” of extrapolating survival curves. Med Decis Mak. 2013;33:369–80.CrossRef
9.
go back to reference Muszbek N, Kreif N, Valderrama A, Benedict A, Ishak J, Ross P. Modelling survival in hepatocellular carcinoma. Curr Med Res Opin. 2012;28:1141–53.CrossRef Muszbek N, Kreif N, Valderrama A, Benedict A, Ishak J, Ross P. Modelling survival in hepatocellular carcinoma. Curr Med Res Opin. 2012;28:1141–53.CrossRef
10.
go back to reference Khor S, Beca J, Krahn M, Hodgson D, Lee L, Crump M, et al. Real world costs and cost-effectiveness of rituximab for diffuse large B-cell lymphoma patients: a population-based analysis. BMC Cancer. 2014;14:586.CrossRef Khor S, Beca J, Krahn M, Hodgson D, Lee L, Crump M, et al. Real world costs and cost-effectiveness of rituximab for diffuse large B-cell lymphoma patients: a population-based analysis. BMC Cancer. 2014;14:586.CrossRef
11.
go back to reference Lee L, Crump M, Khor S, Hoch JS, Luo J, Bremner K, et al. Impact of rituximab on treatment outcomes of patients with diffuse large b-cell lymphoma: a population-based analysis. Br J Haematol. 2012;158:481–8.CrossRef Lee L, Crump M, Khor S, Hoch JS, Luo J, Bremner K, et al. Impact of rituximab on treatment outcomes of patients with diffuse large b-cell lymphoma: a population-based analysis. Br J Haematol. 2012;158:481–8.CrossRef
13.
go back to reference Wan X, Liubao P, Yuanjian L. A review and comparison of methods for recreating individual patient data from published Kaplan–Meier survival curves for economic evaluations: a simulation study. PLoS One. 2015;10:3e0121353. Wan X, Liubao P, Yuanjian L. A review and comparison of methods for recreating individual patient data from published Kaplan–Meier survival curves for economic evaluations: a simulation study. PLoS One. 2015;10:3e0121353.
14.
go back to reference Guidelines for the economic evaluation of health technologies: Canada. 4th ed. Ottawa: CADTH; 2017. Guidelines for the economic evaluation of health technologies: Canada. 4th ed. Ottawa: CADTH; 2017.
15.
go back to reference Mittmann N, Evans WK, Rocchi A, Longo CJ, Au H-J, Husereau D, et al. Addendum to CADTH’s Guidelines for the Economic Evaluation of Health Technologies: Specific Guidance for Oncology Products. Ottawa, ON: Canadian Agency for Drugs and Technologies in Health; 2009. Mittmann N, Evans WK, Rocchi A, Longo CJ, Au H-J, Husereau D, et al. Addendum to CADTH’s Guidelines for the Economic Evaluation of Health Technologies: Specific Guidance for Oncology Products. Ottawa, ON: Canadian Agency for Drugs and Technologies in Health; 2009.
Metadata
Title
A Comparison of Different Analysis Methods for Reconstructed Survival Data to Inform Cost‑Effectiveness Analysis
Authors
Sandjar Djalalov
Jaclyn Beca
Emmanuel M. Ewara
Jeffrey S. Hoch, PhD
Publication date
01-12-2019
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue 12/2019
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.1007/s40273-019-00830-4

Other articles of this Issue 12/2019

PharmacoEconomics 12/2019 Go to the issue

Acknowledgement to Referees

Acknowledgement to Referees